Annals of the New York Academy of Sciences

Cover image for Vol. 1187 Addiction Reviews 2

February 2010

Volume 1187 Addiction Reviews 2

Pages 1–402

  1. Introduction

    1. Top of page
    2. Introduction
    3. Preface
    4. Part I. Medications for addiction and relevant neurotransmitter systems
    5. Part II. Drug and HIV toxicities
    6. Part III. Physiology
    7. Part IV. Imaging
    8. Part V. Development
    9. Part VI. Genetics
    10. Part VII. Behavioral mechanisms
    11. Part VIII. Comorbidity
    12. Part IX. Nonsubstance addictions
    13. Part X. Molecules for addiction
    14. Part XI. Epidemiology
    15. Part XII. Places and institutions
    1. Introduction to Addiction Reviews 2 (pages 1–2)

      George R. Uhl and for the Editorial Advisory Board

      Article first published online: 18 FEB 2010 | DOI: 10.1111/j.1749-6632.2009.05418.x

  2. Preface

    1. Top of page
    2. Introduction
    3. Preface
    4. Part I. Medications for addiction and relevant neurotransmitter systems
    5. Part II. Drug and HIV toxicities
    6. Part III. Physiology
    7. Part IV. Imaging
    8. Part V. Development
    9. Part VI. Genetics
    10. Part VII. Behavioral mechanisms
    11. Part VIII. Comorbidity
    12. Part IX. Nonsubstance addictions
    13. Part X. Molecules for addiction
    14. Part XI. Epidemiology
    15. Part XII. Places and institutions
    1. Preface to Addiction Reviews 2 (page 3)

      George F. Koob

      Article first published online: 18 FEB 2010 | DOI: 10.1111/j.1749-6632.2009.05431.x

  3. Part I. Medications for addiction and relevant neurotransmitter systems

    1. Top of page
    2. Introduction
    3. Preface
    4. Part I. Medications for addiction and relevant neurotransmitter systems
    5. Part II. Drug and HIV toxicities
    6. Part III. Physiology
    7. Part IV. Imaging
    8. Part V. Development
    9. Part VI. Genetics
    10. Part VII. Behavioral mechanisms
    11. Part VIII. Comorbidity
    12. Part IX. Nonsubstance addictions
    13. Part X. Molecules for addiction
    14. Part XI. Epidemiology
    15. Part XII. Places and institutions
  4. Part II. Drug and HIV toxicities

    1. Top of page
    2. Introduction
    3. Preface
    4. Part I. Medications for addiction and relevant neurotransmitter systems
    5. Part II. Drug and HIV toxicities
    6. Part III. Physiology
    7. Part IV. Imaging
    8. Part V. Development
    9. Part VI. Genetics
    10. Part VII. Behavioral mechanisms
    11. Part VIII. Comorbidity
    12. Part IX. Nonsubstance addictions
    13. Part X. Molecules for addiction
    14. Part XI. Epidemiology
    15. Part XII. Places and institutions
    1. Amphetamine toxicities : Classical and emerging mechanisms (pages 101–121)

      Bryan K. Yamamoto, Anna Moszczynska and Gary A. Gudelsky

      Article first published online: 8 JAN 2010 | DOI: 10.1111/j.1749-6632.2009.05141.x

  5. Part III. Physiology

    1. Top of page
    2. Introduction
    3. Preface
    4. Part I. Medications for addiction and relevant neurotransmitter systems
    5. Part II. Drug and HIV toxicities
    6. Part III. Physiology
    7. Part IV. Imaging
    8. Part V. Development
    9. Part VI. Genetics
    10. Part VII. Behavioral mechanisms
    11. Part VIII. Comorbidity
    12. Part IX. Nonsubstance addictions
    13. Part X. Molecules for addiction
    14. Part XI. Epidemiology
    15. Part XII. Places and institutions
    1. Synaptic plasticity in the mesolimbic system : Therapeutic implications for substance abuse (pages 129–139)

      Billy T. Chen, F. Woodward Hopf and Antonello Bonci

      Article first published online: 8 JAN 2010 | DOI: 10.1111/j.1749-6632.2009.05154.x

  6. Part IV. Imaging

    1. Top of page
    2. Introduction
    3. Preface
    4. Part I. Medications for addiction and relevant neurotransmitter systems
    5. Part II. Drug and HIV toxicities
    6. Part III. Physiology
    7. Part IV. Imaging
    8. Part V. Development
    9. Part VI. Genetics
    10. Part VII. Behavioral mechanisms
    11. Part VIII. Comorbidity
    12. Part IX. Nonsubstance addictions
    13. Part X. Molecules for addiction
    14. Part XI. Epidemiology
    15. Part XII. Places and institutions
  7. Part V. Development

    1. Top of page
    2. Introduction
    3. Preface
    4. Part I. Medications for addiction and relevant neurotransmitter systems
    5. Part II. Drug and HIV toxicities
    6. Part III. Physiology
    7. Part IV. Imaging
    8. Part V. Development
    9. Part VI. Genetics
    10. Part VII. Behavioral mechanisms
    11. Part VIII. Comorbidity
    12. Part IX. Nonsubstance addictions
    13. Part X. Molecules for addiction
    14. Part XI. Epidemiology
    15. Part XII. Places and institutions
  8. Part VI. Genetics

    1. Top of page
    2. Introduction
    3. Preface
    4. Part I. Medications for addiction and relevant neurotransmitter systems
    5. Part II. Drug and HIV toxicities
    6. Part III. Physiology
    7. Part IV. Imaging
    8. Part V. Development
    9. Part VI. Genetics
    10. Part VII. Behavioral mechanisms
    11. Part VIII. Comorbidity
    12. Part IX. Nonsubstance addictions
    13. Part X. Molecules for addiction
    14. Part XI. Epidemiology
    15. Part XII. Places and institutions
    1. Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment (pages 184–207)

      Vadim Yuferov, Orna Levran, Dmitri Proudnikov, David A. Nielsen and Mary Jeanne Kreek

      Article first published online: 8 JAN 2010 | DOI: 10.1111/j.1749-6632.2009.05275.x

    2. Addictions and their familiality in Iceland (pages 208–217)

      Thorarinn Tyrfingsson, Thorgeir E. Thorgeirsson, Frank Geller, Valgerdur Runarsdóttir, Ingunn Hansdóttir, Gyda Bjornsdottir, Anna K. Wiste, Gudrun A. Jonsdottir, Hreinn Stefansson, Jeffrey R. Gulcher, Hogni Oskarsson, Daniel Gudbjartsson and Kari Stefansson

      Article first published online: 8 JAN 2010 | DOI: 10.1111/j.1749-6632.2009.05151.x

    3. Transgenic mice in the study of drug addiction and the effects of psychostimulant drugs (pages 218–246)

      Ichiro Sora, BingJin Li, Moe Igari, F. Scott Hall and Kazutaka Ikeda

      Article first published online: 8 JAN 2010 | DOI: 10.1111/j.1749-6632.2009.05276.x

  9. Part VII. Behavioral mechanisms

    1. Top of page
    2. Introduction
    3. Preface
    4. Part I. Medications for addiction and relevant neurotransmitter systems
    5. Part II. Drug and HIV toxicities
    6. Part III. Physiology
    7. Part IV. Imaging
    8. Part V. Development
    9. Part VI. Genetics
    10. Part VII. Behavioral mechanisms
    11. Part VIII. Comorbidity
    12. Part IX. Nonsubstance addictions
    13. Part X. Molecules for addiction
    14. Part XI. Epidemiology
    15. Part XII. Places and institutions
  10. Part VIII. Comorbidity

    1. Top of page
    2. Introduction
    3. Preface
    4. Part I. Medications for addiction and relevant neurotransmitter systems
    5. Part II. Drug and HIV toxicities
    6. Part III. Physiology
    7. Part IV. Imaging
    8. Part V. Development
    9. Part VI. Genetics
    10. Part VII. Behavioral mechanisms
    11. Part VIII. Comorbidity
    12. Part IX. Nonsubstance addictions
    13. Part X. Molecules for addiction
    14. Part XI. Epidemiology
    15. Part XII. Places and institutions
  11. Part IX. Nonsubstance addictions

    1. Top of page
    2. Introduction
    3. Preface
    4. Part I. Medications for addiction and relevant neurotransmitter systems
    5. Part II. Drug and HIV toxicities
    6. Part III. Physiology
    7. Part IV. Imaging
    8. Part V. Development
    9. Part VI. Genetics
    10. Part VII. Behavioral mechanisms
    11. Part VIII. Comorbidity
    12. Part IX. Nonsubstance addictions
    13. Part X. Molecules for addiction
    14. Part XI. Epidemiology
    15. Part XII. Places and institutions
    1. Shared brain vulnerabilities open the way for nonsubstance addictions: Carving addiction at a new joint? (pages 294–315)

      Joseph Frascella, Marc N. Potenza, Lucy L. Brown and Anna Rose Childress

      Article first published online: 29 JAN 2010 | DOI: 10.1111/j.1749-6632.2009.05420.x

  12. Part X. Molecules for addiction

    1. Top of page
    2. Introduction
    3. Preface
    4. Part I. Medications for addiction and relevant neurotransmitter systems
    5. Part II. Drug and HIV toxicities
    6. Part III. Physiology
    7. Part IV. Imaging
    8. Part V. Development
    9. Part VI. Genetics
    10. Part VII. Behavioral mechanisms
    11. Part VIII. Comorbidity
    12. Part IX. Nonsubstance addictions
    13. Part X. Molecules for addiction
    14. Part XI. Epidemiology
    15. Part XII. Places and institutions
  13. Part XI. Epidemiology

    1. Top of page
    2. Introduction
    3. Preface
    4. Part I. Medications for addiction and relevant neurotransmitter systems
    5. Part II. Drug and HIV toxicities
    6. Part III. Physiology
    7. Part IV. Imaging
    8. Part V. Development
    9. Part VI. Genetics
    10. Part VII. Behavioral mechanisms
    11. Part VIII. Comorbidity
    12. Part IX. Nonsubstance addictions
    13. Part X. Molecules for addiction
    14. Part XI. Epidemiology
    15. Part XII. Places and institutions
  14. Part XII. Places and institutions

    1. Top of page
    2. Introduction
    3. Preface
    4. Part I. Medications for addiction and relevant neurotransmitter systems
    5. Part II. Drug and HIV toxicities
    6. Part III. Physiology
    7. Part IV. Imaging
    8. Part V. Development
    9. Part VI. Genetics
    10. Part VII. Behavioral mechanisms
    11. Part VIII. Comorbidity
    12. Part IX. Nonsubstance addictions
    13. Part X. Molecules for addiction
    14. Part XI. Epidemiology
    15. Part XII. Places and institutions

SEARCH

SEARCH BY CITATION